Search

Background: Acute ST-elevation myocardial infarction (STEMI) is the most devastating form of coronary artery disease (CAD). The aim of the present study was to assess the risk factors, clinical presentation, angiographic profile and 30-day outcomes of young patients (aged ≤35 years) with STEMI. Materials and Methods: Between 1 March, 2019 and 29 February, 2020, a total of 75 young patients aged ≤35 years old, with acute STEMI were included in the study. All patients underwent coronary angiography and were evaluated for clinical presentation, risk factors for CAD, management and in hospital and 30-day outcome. Results: The mean age of patients was 31 ± 4.5 years and 96% were male. The most common cardiovascular risk factor was smoking (66.7%), followed by dyslipidaemia (61%), family history of CAD (40%) and obesity (33.3%). Diabetes mellitus (9.3%) and hypertension (14.7%) were less common. Novel risk factors such as high-sensitivity C-reactive protein, lipoprotein (a) and hyperhomocysteinaemia were having significant association to young myocardial infarction (MI). The most common location of MI was the anterior wall (68%). Significant CAD was found in 86.7% of patients. Most patients had single vessel disease (68%) with left anterior descending being the most common vessel involved (53.3%). There was no mortality during hospitalisation or 30-day period. Conclusion: Acute MI in young (≤35 years) almost exclusively occurs in male and smoking is the most common cardiovascular risk factor. Young patients have less extensive coronary involvement and favourable outcomes.

Summary of the Consensus Statement: This statement has been prepared keeping Indian heart failure patients in mind. Optimal management of CHF improves quality of life, reduces hospitalization rates and prolongs survival for people with this condition. Echocardiography is the single most useful test in the evaluation of heart failure, and is necessary to confirm the diagnosis. Plasma B-natriuretic peptide (BNP) measurements may be useful in excluding CHF but not mandatory in India. Educate people with CHF about lifestyle changes (e.g., increase physical activity levels, reduce salt intake and manage weight). Educate people with CHF about CHF symptoms and how to manage fluid load. Avoid prescribing drugs that exacerbate CHF. Prescribe angiotensin-converting enzyme inhibitors (ACEI) at effective doses for people with all grades of systolic heart failure, and titrate to the highest recommended dose tolerated. Angiotensin II receptor antagonists (ARA) may be used as alternatives in people who cannot tolerate ACEIs. Mineralocorticoid receptor antagonists (MRAs) should also be used. For people with stabilised systolic heart failure, prescribe beta-blockers that have been shown to improve outcome in heart failure (e.g., bisoprolol, carvedilol, extended release metoprolol or nebivolol). Titrate to the highest recommended dose tolerated. Prescribe diuretics, digoxin and nitrates for people already using ACEIs and beta-blockers to manage symptoms as indicated. For people who have systolic heart failure (New York Heart Association (NYHA) Class II-IV) despite appropriate doses of ACEIs and diuretics, consider prescribing spironolactone. Eplerenone can be considered in certain setting especially post myocardial infarction though it is more expensive. Consider direct sinus node inhibition with ivabradine for people with CHF who have impaired systolic function, have had a recent heart failure hospitalisation and are in sinus rhythm with a heart rate >70 bpm despite beta blockers or where beta blockers are contraindicated Check for, and treat, iron deficiency in people with CHF to improve their symptoms, exercise tolerance and quality of life Consider assessing people with CHF for biventricular pacemakers and implantable defibrillators. Patients with end stage heart failure have an option for heart transplant and ventricular assist devices which is now available in select centers.

Isolated annular dilatation is an extremely uncommon cause of congenital mitral regurgitation. We report a case of a 5-year-old child with idiopathic isolated annular dilatation causing severe congenital mitral regurgitation.